Menopause assessment, treatment, and patient education

Nurse Practitioner

Volumn 30, Issue 2, 2005, Pages 32-43

  Smith, Patricia E ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; DIET THERAPY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; METHODOLOGY; MIDDLE AGED; NURSING ASSESSMENT; PATIENT EDUCATION; PHYSIOLOGY; REVIEW;

COMPLEMENTARY THERAPIES; DIET THERAPY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NURSING ASSESSMENT; PATIENT EDUCATION;

EID: 18444411346     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200502000-00006     Document Type: Article

References (38)

1. United States Bureau of the Census. Current population reports, Available at: 2000.gov. Accessed January 17, 2005.
2. Utian WH: The International Menopause Society menopause-related terminology definitions. Climacteric 1999; 2:284-86.
3. Woods NF, Mitchell ES: Anticipating menopause: observations from the Seattle Midlife Women’s Health Study. Menopause 1999; 6: 167-73.
4. HEDIS - The Health Plan Employer Data and Information Set. Specifications for Survey Measures. Washington, DC: National Committee for Quality Assurance; Vol 3. 2000 131-159.
5. Mort EA: HEDIS and menopause counseling: the management of menopause measure. Menop Mgmt 2001; 10: 9-12.
6. Andrews WC, Morrow TJ: HEDIS measure for the management of menopause. Am J of Mgd Care 2000; 14: S742 - 45.
7. The North American Menopause Society. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of the North American Menopause Society. Menopause 1998; 5: 69-76m.
8. Hulley S, Grady D, Bush T, Furberg et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
9. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
10. Karas RH, Clarkson TB: Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menop Med 2003; 10: 4: 8-12.
11. Writing Group for the Women’s Health Initiative Investigators - unopposed estrogen arm and risk for breast cancer - publication in process.
12. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90: 814-29.
13. Bush TL, Whiteman M, Flaws J: Hormone replacement therapy: a qualitative review. Obstet Gynecol 2001; 98:498-508.
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 198,411 women without breast cancer. Lancet 1997; 350:1047-59
15. Schairer C, Lubin J, Troisi R, et al: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-91.
16. Vestergaard P, Herman AP, Gram J: Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28: 137 - 45.
17. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med May 8, 2003; 348.
18. Hlatky MA, Boothroyd D, Vittinghoff E, et al: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group: Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial [comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial]. JAMA 2002 Feb; 287(5):591-7.
19. Brett KM, Madans JH: Differences in use of postmenopausal hormone replacement therapy by black and white women. Menopause 1997; 4: 66-70.
20. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J of Epidemiol 1997; 145: 536-45.
21. Shumaker SA, Legault C, Rapp SR, et al for the WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651-62.
22. Zandi PP, Carlson MC, Plassman BL, et al: Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002; 288:2123-29.
23. Stearns V, Beebe KL, Iyengar M, et al: Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA 2003; 289, 21, 2827-33.
24. Stearns V, Isaacs C, Rowland J, et al: A pilot trial assessing the efficacy of paraoxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17-22.
25. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356:2059-63.
26. Loprinzi CL, Sloan JA, Perez EA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20:1578-83.
27. Guttuso T, Kurlan R, McDermott MP, et al: Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obst & Gyne; 2003; 101(2): 337 - 45.
28. Wren BG, Champion SM, Manga RZ, et al: Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003; 10: 13-18.
29. Faure Ed, Chantre P, Mares P: Effects of a standardized soy extract on hot flashes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002; 9:329-34.
30. Knight DC, Howes JB, Eden JA: The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2:79-84.
31. Albertazzi P, Pansini F, BonaccorsiG, et al: The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6-11.
32. Taylor M: Alternative medicine and the perimenopause: an evidence-based review. Obst and Gyne Clin 2002; 29 (3): 1-17.
33. NAMS Report. Amended report from the NAMS Advisory Panel on Response to Women’s Health Initiative study results by The American College of Obstetricians and Gynecologists. Washington: Am Col Obst and Gyn Oct 1, 2002. Available at:. Accessed January 17, 2005.
34. Utian WH, Janata JW, Kingsberg SA, et al: The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002; 9(6): 402-09.
35. McClung MR, Geusens P, Miller PD, et al: Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
36. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12.
37. National Osteoporosis Foundation: Physician’s Guide to Prevention and Treatment of Osteoporosis, 2003. Available at. Accessed January 17, 2005.
38. Kaunitz A: Oral contraceptive use in perimenopause. Am J Obset Gynecol 2001; 185(2): S32-37.